Altogether we present evidence that synthetic lethality using ATM/CHK2 inhibitors can be exploited to treat cervical cancer and other tumors in which p53 expression is inactivated by gene mutation or deletion. This evidence concerns the gene CHEK2 and cervical carcinoma.